Gilead Sciences Inc.
History
| Year | Detail |
|---|---|
| 1987 | Gilead founded. |
| 1990 | AmBisome approved (in Europe). |
| 1991 | Nucleotides in-licensed from IOCB Rega. |
| 1996 | Vistide approved. |
| 1999 | NeXstar acquired (establishment of European operations). |
| 2001 | Viread approved. |
| 2002 | Hepsera approved. |
| 2003 | Acquired Triangle Pharmaceuticals. |
| 2004 | Truvada approved. |
| 2007 | Cork, Ireland, manufacturing facility acquired from Nycomed. |
| 2008 | Viread for hepatitis B approved; Lexiscan approved. |
| 2010 | Cayston approved; CGI Pharmaceuticals acquired. |
| 2011 | Acquired Arresto BioSciences and Calistoga Pharmaceuticals. |
| 2012 | Acquired Pharmasset. |
| 2013 | Acquired YM BioSciences. |
| 2022 | Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies. |
| 2023 | Gilead Sciences and Arcus Biosciences Expand Partnership. |
| 2024 | Gilead Sciences acquisition of CymaBay Therapeutics. |
BCC Research Beacon 